Journal of Clinical Medicine (Jan 2023)

Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

  • Ivan J. Núñez-Gil,
  • Gisela Feltes,
  • María C. Viana-Llamas,
  • Sergio Raposeiras-Roubin,
  • Rodolfo Romero,
  • Emilio Alfonso-Rodríguez,
  • Aitor Uribarri,
  • Francesco Santoro,
  • Víctor Becerra-Muñoz,
  • Martino Pepe,
  • Alex F. Castro-Mejía,
  • Jaime Signes-Costa,
  • Adelina Gonzalez,
  • Francisco Marín,
  • Javier Lopez-País,
  • Enrico Cerrato,
  • Olalla Vázquez-Cancela,
  • Carolina Espejo-Paeres,
  • Álvaro López Masjuan,
  • Lazar Velicki,
  • Ibrahim El-Battrawy,
  • Harish Ramakrishna,
  • Antonio Fernandez-Ortiz,
  • Julián Perez-Villacastín

DOI
https://doi.org/10.3390/jcm12020706
Journal volume & issue
Vol. 12, no. 2
p. 706

Abstract

Read online

Background: Heart disease is linked to worse acute outcomes after coronavirus disease 2019 (COVID-19), although long-term outcomes and prognostic factor data are lacking. We aim to characterize the outcomes and the impact of underlying heart diseases after surviving COVID-19 hospitalization. Methods: We conducted an analysis of the prospective registry HOPE-2 (Health Outcome Predictive Evaluation for COVID-19-2, NCT04778020). We selected patients discharged alive and considered the primary end-point all-cause mortality during follow-up. As secondary main end-points, we included any readmission or any post-COVID-19 symptom. Clinical features and follow-up events are compared between those with and without cardiovascular disease. Factors with p heart disease: 2.63, 95% CI: 1.81–3.84). Vaccination was found to be an independent protector factor (HR all-cause death: 0.09; 95% CI: 0.04–0.19). Conclusions: After surviving the acute phase, patients with underlying heart disease continue to present a more complex clinical profile and worse outcomes including increased mortality. The COVID-19 vaccine could benefit survival in patients with heart disease during follow-up.

Keywords